

CONTENTS

CONTRIBUTORS	xi
PREFACE	xv
ACKNOWLEDGMENTS	xix

1. Pharmacometrics: Impacting Drug Development and Pharmacotherapy	1
<i>Paul J. Williams and Ene I. Ette</i>	

PART I GENERAL PRINCIPLES

2. General Principles of Programming: Computer and Statistical	25
<i>Sastry S. Isukapalli and Amit Roy</i>	
3. Validation of Software for Pharmacometric Analysis	53
<i>Gary L. Wolk</i>	
4. Linear, Generalized Linear, and Nonlinear Mixed Effects Models	103
<i>Farkad Ezzet and José C. Pinheiro</i>	
5. Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods	137
<i>Stephen B. Duffull, Lena E. Friberg, and Chantaratsamon Dansirikul</i>	
6. Estimating the Dynamics of Drug Regimen Compliance	165
<i>Ene I. Ette and Alaa Ahmad</i>	
7. Graphical Displays for Modeling Population Data	183
<i>E. Niclas Jonsson, Mats O. Karlsson, and Peter A. Milligan</i>	
8. The Epistemology of Pharmacometrics	223
<i>Paul J. Williams, Yong Ho Kim, and Ene I. Ette</i>	
9. Data Imputation	245
<i>Ene I. Ette, Hui-May Chu, and Alaa Ahmad</i>	

PART II POPULATION PHARMACOKINETIC BASIS OF PHARMACOMETRICS

10. Population Pharmacokinetic Estimation Methods	265
<i>Ene I. Ette, Paul J. Williams, and Alaa Ahmad</i>	

11. Timing and Efficiency in Population Pharmacokinetic/ Pharmacodynamic Data Analysis Projects	287
<i>Siv Jönsson and E. Niclas Jonsson</i>	
12. Designing Population Pharmacokinetic Studies for Efficient Parameter Estimation	303
<i>Ene I. Ette and Amit Roy</i>	
13. Population Models for Drug Absorption and Enterohepatic Recycling	345
<i>Olivier Pétricol, Valérie Cosson, Eliane Fuseau, and Mathilde Marchand</i>	
14. Pharmacometric Knowledge Discovery from Clinical Trial Data Sets	383
<i>Ene I. Ette</i>	
15. Resampling Techniques and Their Application to Pharmacometrics	401
<i>Paul J. Williams and Yong Ho Kim</i>	
16. Population Modeling Approach in Bioequivalence Assessment	421
<i>Chuanpu Hu and Mark E. Sale</i>	
 PART III PHARMACOKINETICS / PHARMACODYNAMICS RELATIONSHIP: BIOMARKERS AND PHARMACOGENOMICS, PK/PD MODELS FOR CONTINUOUS DATA, AND PK/PD MODELS FOR OUTCOMES DATA	
17. Biomarkers in Drug Development and Pharmacometric Modeling	457
<i>Paul J. Williams and Ene I. Ette</i>	
18. Analysis of Gene Expression Data	473
<i>Daniel Brazeau and Murali Ramanathan</i>	
19. Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling	509
<i>Jin Y. Jin and William J. Jusko</i>	
20. Empirical Pharmacokinetic/Pharmacodynamic Models	529
<i>James A. Uchizono and James R. Lane</i>	
21. Developing Models of Disease Progression	547
<i>Diane R. Mould</i>	
22. Mechanistic Pharmacokinetic/Pharmacodynamic Models I	583
<i>Varun Garg and Ariya Khunvichai</i>	
23. Mechanistic Pharmacokinetic/Pharmacodynamic Models II	607
<i>Donald E. Mager and William J. Jusko</i>	
24. PK/PD Analysis of Binary (Logistic) Outcome Data	633
<i>Jill Fiedler-Kelly</i>	
25. Population Pharmacokinetic/Pharmacodynamic Modeling of Ordered Categorical Longitudinal Data	655
<i>Ene I. Ette, Amit Roy, and Partha Nandy</i>	

- 26. Transition Models in Pharmacodynamics** 689
Ene I. Ette
- 27. Mixed Effects Modeling Analysis of Count Data** 699
Christopher J. Godfrey
- 28. Mixture Modeling with NONMEM V** 723
Bill Frame

PART IV CLINICAL TRIAL DESIGNS

- 29. Designs for First-Time-in-Human Studies in Nononcology Indications** 761
Hui-May Chu, JiuHong Zha, Amit Roy, and Ene I. Ette
- 30. Design of Phase 1 Studies in Oncology** 781
Brigitte Tranchand, René Bruno, and Gilles Freyer
- 31. Design and Analysis of Clinical Exposure: Response Trials** 803
*David Hermann, Raymond Miller, Matthew Hutmacher, Wayne Ewy,
and Kenneth Kowalski*

PART V PHARMACOMETRIC KNOWLEDGE CREATION

- 32. Pharmacometric/Pharmacodynamic Knowledge Creation: Toward
Characterizing an Unexplored Region of the Response Surface** 829
Ene I. Ette and Hui-May Chu
- 33. Clinical Trial Simulation: Theory** 851
Peter L. Bonate
- 34. Modeling and Simulation: Planning and Execution** 873
Paul J. Williams and James R. Lane
- 35. Clinical Trial Simulation: Efficacy Trials** 881
Matthew M. Riggs, Christopher J. Godfrey, and Marc R. Gastanguay

PART VI PHARMACOMETRIC SERVICE AND COMMUNICATION

- 36. Engineering a Pharmacometrics Enterprise** 903
Thaddeus H. Grasela and Charles W. Dement
- 37. Communicating Pharmacometric Analysis Outcome** 925
Ene I. Ette and Leonard C. Onyiah

PART VII SPECIFIC APPLICATION EXAMPLES

- 38. Pharmacometrics Applications in Population Exposure–Response
Data for New Drug Development and Evaluation** 937
He Sun and Emmanuel O. Fadiran

39. Pharmacometrics in Pharmacotherapy and Drug Development: Pediatric Application	955
<i>Edmund V. Capparelli and Paul J. Williams</i>	
40. Pharmacometric Methods for Assessing Drug-Induced QT and QTc Prolongations for Non-antiarrhythmic Drugs	977
<i>He Sun</i>	
41. Using Pharmacometrics in the Development of Therapeutic Biological Agents	993
<i>Diane R. Mould</i>	
42. Analysis of Quantic Pharmacokinetic Study: Robust Estimation of Tissue-to-Plasma Ratio	1035
<i>Hui-May Chu and Ene I. Ette</i>	
43. Physiologically Based Pharmacokinetic Modeling: Inhalation, Ingestion, and Dermal Absorption	1069
<i>Sastry S. Isukapalli, Amit Roy, and Panos G. Georgopoulos</i>	
44. Modeling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set: An Application	1107
<i>Valérie Cosson, Karin Jorga, and Eliane Fuseau</i>	
45. Characterizing Nonlinear Pharmacokinetics: An Example Scenario for a Therapeutic Protein	1137
<i>Stuart Friedrich</i>	
46. Development, Evaluation, and Applications of in Vitro/in Vivo Correlations: A Regulatory Perspective	1157
<i>Patrick J. Marroum</i>	
47. The Confluence of Pharmacometric Knowledge Discovery and Creation in the Characterization of Drug Safety	1175
<i>Hui-May Chu and Ene I. Ette</i>	
INDEX	1197